ArticleTranslational oncology2025
Development and validation of nomogram including mutations in angiogenesis-related genes as risk factors for HCC patients treated with TACE.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Roles of the Membrane-Anchored Glycoprotein RECK in Animal Development, Tumor Suppression, and Beyond.Life (Basel, Switzerland) · 2026Review
- SERPINA1 drives TACE resistance in hepatocellular carcinoma by competitively binding ITGB3 to block ITCH-mediated ubiquitination and degradation.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Multimodal analysis reveals potential association of CDH13 with endothelial cells and its overexpression in hepatocellular carcinoma.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a vascular-rich solid tumor, hepatocellular carcinoma (HCC) patients with poor transarterial chemoembolization (TACE) respone or treatment failure may correlate with tumor angiogenesis in residual disease. However, their relationship remains unclear. This study aims to explore the relationship between angiogenesis-related genes and TACE failure in patients with HCC and to develop a predictive model for assessing treatment outcomes. MATERIALS AND
methodsSomatic mutation profiles of 165 patients with HCC treated with TACE were analyzed using whole-exome sequencing (WES). Multivariate Cox regression analysis was performed to calculate the genetic risk score (GRS) for angiogenesis-related gene mutations. The participants were randomly divided into training and validation groups. In the training set, independent prognostic factors of TACE-treated patients with HCC were screened using univariate Cox-LASSO-stepwise Cox regression, and a nomogram was established and evaluated using the receiver operating characteristic curve, calibration curve, and decision curve analysis of the two sets.
resultsAmong 165 patients, significant genetic alterations were identified, with TP53 being the most frequently mutated gene. Mutations in FGFR4, MST1R, and RECK were associated with the treatment efficacy of patients receiving TACE treatment, and the constructed GRS was associated with poor prognosis. Furthermore, AFP, ALT, AST, PLR, PD-L1 immune drug treatment, and GRS were confirmed as independent factors affecting the prognosis of patients with HCC treated with TACE. A nomogram was constructed, which demonstrated excellent discrimination, calibration, and clinical benefits in both the training and validation sets.
conclusionThese findings highlight the critical role of angiogenesis-related genes in predicting TACE outcomes in patients with HCC and indicate that the developed prognostic model and nomogram can serve as valuable tools to predict prognosis based on the GRS of angiogenesis-associated gene mutations. IMPLICATIONS FOR PRACTICE: Our findings highlight the critical role of angiogenesis-related genes in predicting TACE outcomes in HCC patients. The developed prognostic model and nomogram can serve as valuable tools for clinicians, enhancing decision-making and treatment strategies for HCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.